Literature DB >> 22722263

Indoleamine 2,3-dioxygenase affects the aggressiveness of intraductal papillary mucinous neoplasms through Foxp3+CD4+CD25+ T cells in peripheral blood.

Tetsuya Ikemoto1, Mitsuo Shimada, Masato Komatsu, Shinichiro Yamada, Yu Saito, Hiroki Mori, Yuji Morine, Satoru Imura, Yoshimi Bando, Tohru Utsunomiya.   

Abstract

OBJECTIVE: Intraductal papillary mucinous neoplasms (IPMNs) have a high malignant potential. We previously reported that peripheral Foxp3(+)CD4(+)CD25(+) T-cell (Foxp3(+) Treg) populations significantly increase with IPMN pathological aggressiveness. Dendritic cell-mediated induction of active Tregs from naive CD4(+) T cells requires indoleamine 2,3-dioxygenase (IDO). Here, we evaluated whether an IDO-Foxp3(+) Treg interaction plays a role in IPMN pathological aggressiveness.
METHODS: We evaluated peripheral blood samples and resected specimens from 12 patients with IPMN. We analyzed Foxp3(+)CD4(+)CD25(+) T cells in peripheral blood by fluorescence-activated cell sorting, evaluated the resected specimens by anti-IDO antibody staining, and compared them with the patients' clinicopathological factors.
RESULTS: The pathological aggressiveness of IPMN was significantly associated with the number of peripheral Foxp3(+) Tregs (P < 0.05) and IDO-positive cells per high-power field (HPF) (P < 0.01). There was a significant correlation between the numbers of peripheral Foxp3(+) Tregs and IDO-positive cells/HPF (r = 0.625, P < 0.01). Patients with 7 or more IDO-positive cells/HPF had a significantly higher recurrence rate than those with less than 7 IDO-positive cells/HPF (P < 0.01, log-rank test).
CONCLUSIONS: Peripheral Foxp3(+) Tregs accurately reflect the aggressiveness of IPMNs. An increase in Foxp3(+) Tregs can be induced by local IDO-positive cells in IPMN.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22722263     DOI: 10.1097/MPA.0b013e3182575e4a

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  6 in total

Review 1.  Stromal reengineering to treat pancreas cancer.

Authors:  Ingunn M Stromnes; Kathleen E DelGiorno; Philip D Greenberg; Sunil R Hingorani
Journal:  Carcinogenesis       Date:  2014-06-07       Impact factor: 4.944

Review 2.  Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal.

Authors:  Clara S Mundry; Kirsten C Eberle; Pankaj K Singh; Michael A Hollingsworth; Kamiya Mehla
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-06-21       Impact factor: 10.680

3.  Changes of immunological parameters with administration of Japanese Kampo medicine (Juzen-Taihoto/TJ-48) in patients with advanced pancreatic cancer.

Authors:  Tetsuya Ikemoto; Mitsuo Shimada; Shuichi Iwahashi; Yu Saito; Mami Kanamoto; Hiroki Mori; Yuji Morine; Satoru Imura; Tohru Utsunomiya
Journal:  Int J Clin Oncol       Date:  2013-02-27       Impact factor: 3.402

Review 4.  Complex role for the immune system in initiation and progression of pancreatic cancer.

Authors:  Kristin S Inman; Amanda A Francis; Nicole R Murray
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

5.  Interferon gamma suppresses collagen-induced arthritis by regulation of Th17 through the induction of indoleamine-2,3-deoxygenase.

Authors:  Jaeseon Lee; Jennifer Lee; Mi-Kyung Park; Mi-Ae Lim; Eun-Mi Park; Eun-Kyung Kim; Eun-Ji Yang; Seon-Yeong Lee; Joo-Yeon Jhun; Sung-Hwan Park; Ho-Youn Kim; Mi-La Cho
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

Review 6.  T Lymphocytes: A Promising Immunotherapeutic Target for Pancreatitis and Pancreatic Cancer?

Authors:  Qi Zhou; Xufeng Tao; Shilin Xia; Fangyue Guo; Chen Pan; Hong Xiang; Dong Shang
Journal:  Front Oncol       Date:  2020-03-24       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.